



# 2nd Symposium on Medicinal Chemistry for Global Health

Sunday 18 - Tuesday 20 June 2017

GlaxoSmithKline, Tres Cantos, Madrid, Spain

Organised by SCI's Fine Chemicals Group and RSC's  
Biological and Medicinal Chemistry Sector



ROYAL SOCIETY  
OF CHEMISTRY

BIOLOGICAL AND  
MEDICINAL  
CHEMISTRY  
SECTOR



**SCI**

where science meets business

## Programme - Sunday 18 June

- 14.30** Registration
- 15.30** **Welcome**  
Head of Site, GSK Tres Cantos and Dr Caroline Low, SCI
- 15.45** **Wellcome and the challenge of diseases of the developing world**  
Dr Ann Mills Duggan, Wellcome Trust, UK
- 16.30** **'All bugs are shallow': open source methods in drug discovery**  
Prof Matthew Todd, University of Sydney, Australia
- 17.15** Refreshment break
- 17.45** ***Plasmodium* target prioritisation by genome scale functional profiling**  
Dr Julian Rayner, Wellcome Trust Sanger Institute, UK
- 18.20** **The NTD drug discovery booster: a novel approach for hit to lead chemistry**  
Dr Benjamin Perry, DNDi, Switzerland
- 18.55** Day 1 close

## Monday 19 June

- 09.05** **Tackling TB targets using fragment-based strategies**  
Prof Chris Abell, University of Cambridge, UK
- 09.50**  **$\beta$ -lactams with unconventional activity against *Mycobacterium tuberculosis***  
Prof Carl Nathan, Weill Cornell Medical College, USA
- 10.25** Refreshments
- 10.55** **New sythetic anti-Tuberculosis Cyclohexylgriselimycin, more than 50 years after the isolation of the natural Griselimycin**  
Dr Evelyne Fontaine, Sanofi, France
- 11.30** **Discovery of a new clinical candidate for the treatment of TB: GSK070**  
Dr Carlos Alemparte, GSK Tres Cantos, Spain
- 12.05** Flash presentation session
- 12.20** Lunch, poster and exhibition viewing
- 14.00** **Targeting protein lipidation in *Plasmodium***  
Prof Ed Tate, Imperial College London and Francis Crick Institute, UK
- 14.35** **A multi-stage preclinical candidate for the potential treatment of malaria (DDD107498: the compound with muscle)**  
Dr Neil Norcross, University of Dundee, UK
- 15.10** **The journey from TCAMS to a clinical candidate. First time disclosure of a novel thiotriazole based antimalarial asset**  
Dr Beatriz Díaz Hernández, GSK Tres Cantos, Spain

- 15.45** Refreshment break
- 16.15** **MMV's strategy and recent advances for *P. vivax* radical cure**  
Dr Brice Campo, MMW, Switzerland
- 16.50** **Identification of GSK3186899A / DDD853651: a preclinical candidate for the treatment of Visceral Leishmaniasis**  
Dr Tim Miles, GSK Tres Cantos, Spain
- 17.25** **Novel antileishmanial agents: amino-pyrazole ureas with potent *in vitro* and *in vivo* activity**  
Dr Gavin Whitlock, Sandexis and DNDi, UK
- 18.00** Day 2 close
- 19.30** Conference dinner

## **Tuesday 20 June**

- 09.00** **Proteasome inhibitors: a single cure for multiple kinetoplastid diseases**  
Dr Advait Nagle, Genomics Institute of the Novartis Research Foundation, USA
- 09.45** **Kinase inhibitor repurposing approaches to lead discovery for neglected tropical diseases**  
Prof Michael Pollastri, Northeastern University, USA
- 10.20** Refreshments
- 10.50** **Identification of a promising candidate to treat cryptosporidiosis**  
Dr Manjunatha Ujjini, Novartis, Singapore
- 11.25** **Gates Foundation perspective on Cryptosporidium**  
Dr Stephen Ward, Gates Foundation, USA
- 12.00** Flash presentation session
- 12.10** Lunch, poster and exhibition viewing
- 13.30** **Optimising treatment for human filariasis: the importance of translational models and human dose predictions**  
Prof Steve Ward, Liverpool School of Tropical Medicine, UK
- 14.00** **Discovery and pre-clinical characterisation of 3rd generation HAP analogues as Hepatitis B virus capsid inhibitors**  
Dr Wei Zhu, Roche, China
- 14.35** **Antivirals, a lot has been achieved, yet a long way to go**  
Prof Johan Neyts, University of Leuven, Belgium
- 15.10** **In the pursuit of ideal hits for antifungal research**  
Dr Stephane Jeanmart, Syngenta, Switzerland
- 15.45** Closing remarks

## Synopsis

This meeting will focus on medicinal chemistry approaches to developing new medicines for diseases affecting global health. Tuberculosis, malaria and diseases caused by a diverse range of pathogens, including flaviviruses (e.g. dengue, West Nile), kinetoplastids (e.g. Chagas disease, leishmaniasis) and parasitic worms (e.g. filariasis), remain a cause of high mortality across the globe. However, an ever-improving understanding of the complex life-cycles of the disease-causing pathogens is presenting increasing opportunities for those seeking to tackle these global health problems. Keynote talks from international experts, alongside perspectives detailing case histories in drug discovery, will highlight the latest developments in the field whilst showcasing the opportunity for creativity and innovation.

## Attendees

Bringing together leading exponents for an exciting spread of themed sessions, the meeting will appeal to anyone with an interest in drug discovery and medicinal chemistry. With great opportunities for collaborative academic-industrial partnerships and open innovation discovery programmes, researchers from both sectors will benefit from the networking opportunities that the meeting will also offer.

## Call for posters

Anyone wishing to present a poster is encouraged to submit a one-page abstract by **Friday 21 April 2017** with "Global Health – Poster Abstract" in the subject line. Selected poster presenters will be given the opportunity to give a flash presentation.

Submit your abstract directly: [conferences@soci.org](mailto:conferences@soci.org).

## Delegate fees

### Early Bird Rate Before 28 April

SCI/RSC Member.....	£195
SCI/RSC Student.....	£80
Non-Member.....	£260

### Standard Rate After 28 April

SCI/RSC Member Rate.....	£275
SCI/RSC Student Rate.....	£115
Non-Member Rate .....	£365

Register online at: [www.soci.org/](http://www.soci.org/)



## Venue

GlaxoSmithKline  
Tres Cantos  
Madrid  
Spain

## Accommodation

Local hotel information can be found on the event webpage. For more information, please visit [bit.ly/MedicinalGlobalHealth](http://bit.ly/MedicinalGlobalHealth).

## Travel

GlaxoSmithKline, Tres Cantos, which is situated approximately one hour by train from Madrid Airport Terminal 4 (with one change at Chamartin station) and 30 minutes from the centre of Madrid. A free shuttle bus runs from outside Terminals 1, 2 and 3 to Terminal 4. More information on the service provider Renfe Cercanias can be found on the event webpage [bit.ly/MedicinalGlobalHealth](http://bit.ly/MedicinalGlobalHealth). It is a 30 minute drive from the airport to Tres Cantos, with taxis costing around €50 for this journey.

## Sponsors



## Organising Committee

- ▶ Dr Mónica Cacho-Izquierdo, GlaxoSmithKline
- ▶ Dr Félix Calderon, GlaxoSmithKline
- ▶ Dr Liam Cox, SCI/University of Birmingham
- ▶ Dr John Cumming, SCI/Roche
- ▶ Dr Caroline Low, SCI/Independent Consultant
- ▶ Dr Maria Marco-Martin, GlaxoSmithKline
- ▶ Dr Cristina Ramos, GlaxoSmithKline
- ▶ Dr Carmen Sanchez-Rodriguez, GlaxoSmithKline
- ▶ Dr Andrew Stachulski, RSC/University of Liverpool



## Continuing Professional Development

In 2015 SCI became a CPD (Continuing Professional Development) Standards Accredited Centre. This means that SCI members are able to gain CPD points by attending eligible SCI conferences.

Continuing professional development (CPD) is the intentional maintenance and development of the knowledge and skills needed to perform in a professional context. This could mean honing current skills, developing them to a new level, or learning entirely new ones, that will allow for an employee's job role to expand or prepare them for potential promotion. Many companies and organisations now prioritise CPD activities and certification because they ensure a constantly progressing workforce.

SCI Members attending this event can claim 13 points.

**The CPD Standards Office**

CPD PROVIDER: 41057

2016 - 2018

[www.cpdstandards.com](http://www.cpdstandards.com)



## Information on SCI

SCI is a forward-looking multidisciplinary membership organisation connecting industry, government and academia to advance the application of science for the benefit of society. SCI offers a network of contacts spanning the chemical and chemical-using industries, together with a rolling programme of conferences, events and prestigious awards which help further knowledge and support those involved in the sector, no matter what stage they're at in their careers.

SCI is the publisher of many well respected peer-reviewed journals and industry leader Chemistry & Industry magazine (C&I).

Join SCI today to network with people across the chemical and chemical-using industries and make connections that spark innovation, get careers moving, and set business ideas rolling.

Visit [www.soci.org/membership](http://www.soci.org/membership) to find out more and join us.



**@SCIUpdate**



**SCI**

where science meets business



# New Synthetic Methods - Application and Design

Thursday 28 September 2017, SCI, London, UK

## Synopsis

The SCI's Fine Chemical Group is pleased to announce a one-day meeting to showcase cutting edge synthetic organic chemistry. The aim of the meeting is to highlight new synthetic approaches, disconnections and methods, and their application as developed by key researchers from both academia and industry. An exciting line up of leading academic and industrial scientists will present a series of lectures covering areas such as photochemical reactions, C–H activation and new catalytic methods.

## Attendees

This meeting will appeal to anyone interested in the latest developments in synthetic organic chemistry, both in industry and in academia. SCI Members can claim CPD points for attending this event.

## Registration Fees

**Early bird fees before 12pm Friday 1 September 2017**

£100.....	SCI Member
£35.....	SCI Student Member
£130.....	Non-Member

**Book today! [bit.ly/SCINewSynth](http://bit.ly/SCINewSynth)**







# 2nd Symposium on Medicinal Chemistry for Global Health

Sunday 18 - Tuesday 20 June 2017

GSK, Tres Cantos, Madrid, Spain

**Organised by SCI's Fine Chemicals Group and RSC's  
Biological and Medicinal Chemistry Sector**



ROYAL SOCIETY  
OF CHEMISTRY

BIOLOGICAL AND  
MEDICINAL  
CHEMISTRY  
SECTOR



**SCI**

where science meets business